In 2022, Kentucky reported the highest cancer incidence rate in the United States, with around 512 new cases of cancer per 100,000 inhabitants. This statistic represents the U.S. states with the highest cancer incidence rates per 100,000 population in 2022.

In 2023, Hawaii had the lowest death rate from cancer among all U.S. states, with around 119 deaths per 100,000 population. The states with the highest cancer death rates at that time were Kentucky, West Virginia, and Mississippi. This statistic shows cancer death rates in the United States in 2023, by state.

In 2022, Utah had the lowest death rate from cancer among all U.S. states with around 116 deaths per 100,000 population. The states with the highest cancer death rates at that time were Mississippi, Kentucky and West Virginia. This statistic shows cancer death rates in the United States in 2022, by state.

The United States Cancer Statistics (USCS) online databases in WONDER provide cancer incidence and mortality data for the United States for the years since 1999, by year, state and metropolitan areas (MSA), age group, race, ethnicity, sex, childhood cancer classifications and cancer site. Report case counts, deaths, crude and age-adjusted incidence and death rates, and 95% confidence intervals for rates. The USCS data are the official federal statistics on cancer incidence from registries having high-quality data and cancer mortality statistics for 50 states and the District of Columbia. USCS are produced by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), in collaboration with the North American Association of Central Cancer Registries (NAACCR). Mortality data are provided by the Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), National Vital Statistics System (NVSS).

It is estimated that in 2025 there will be a total of 226,650 new cases of lung and bronchus cancer in the United States. The highest number of these cases are estimated to be in the state of Florida. This statistic presents the estimated number of new lung and bronchus cancer cases in the United States in 2025, by state.

In 2021, there were around *** new cases of breast cancer per 100,000 population in the state of Connecticut, making it the state with the highest breast cancer incidence rate that year. This statistic shows the incidence rate of breast cancer in the U.S. in 2021, by state.

The graph illustrates the number of deaths from cancer in the United States over the period from 1999 to 2022. The x-axis represents the years, labeled with two-digit abbreviations from '99 to '22, while the y-axis displays the annual number of cancer-related deaths. Throughout this 24-year span, the number of deaths ranges from a minimum of 549,829 in 1999 to a maximum of 608,366 in 2022. The data shows a gradual increase in annual deaths over the years. Notably, the number surpassed 550,000 in 2000 with 553,080 deaths, reached 574,738 in 2010, and exceeded 600,000 in 2020 with 602,347 deaths. The figures continued to rise, culminating in the highest recorded number of 608,366 deaths in 2022.

Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

What are Cancer Statistics in US States?

The circled group of good survivors has genetic indicators of poor survivors (i.e. low ESR1 levels, which is typically the prognostic indicator of poor outcomes in breast cancer) – understanding this group could be critical for helping improve mortality rates for this disease. Why this group survived was quickly analysed by using the Outcome Column (here Event Death - which is binary - 0,1) as a Data Lens (which we term Supervised vs Unsupervised analyses).

How to use this dataset

• A network was built using only gene expression with 272 breast cancer patients (as rows), and 1570 columns.

• Metadata includes patient info, treatment, and survival.

• Each node is a group of patients similar to each other. Flares (left) represent sub-populations that are distinct from the larger population. (One differentiating factor between the two flares is estrogen expression (low = top flare, high = bottom flare)).

• A bottom flare is a group of patients with 100% survival. The top flare shows a range of survival – very poor towards the tip (red), and very good near the base (circled).

Acknowledgments

When we use this dataset in our research, we credit the authors as :

• License : CC BY 4.0.

• This data set is taken from https://query.data.world/s/yi422lv7mkhnydnt4ixrfujmoaglpk .

The main idea for uploading this dataset is to practice data analysis with my students, as I am working in college and want my student to train our studying ideas in a big dataset, It may be not up to date and I mention the collecting years, but it is a good resource of data to practice

The graph displays the total number of new cancer cases in the U.S. from 1999 to 2022. The x-axis represents the years, while the y-axis shows the total number of new cancer cases reported each year. The data shows a steady increase in new cancer cases over the years, with the highest number recorded in 2021, at 1,869,872 cases. The lowest number occurred in 1999, with 1,304,271 cases. A notable dip in 2020 reflects the impact of the COVID-19 pandemic, with cases dropping to 1,718,755 before rising again in 2021. The data highlights the growing prevalence of cancer cases in the U.S. over two decades.

SEER Limited-Use cancer incidence data with associated population data. Geographic areas available are county and SEER registry. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute collects and distributes high quality, comprehensive cancer data from a number of population-based cancer registries. Data include patient demographics, primary tumor site, morphology, stage at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and survival rates within each stage.

One woman in nine can expect to develop breast cancer during her lifetime and one in 25 will die from the disease. Statistically low incidences of breast cancer are found in Newfoundland and Labrador, the territories, and northern areas of most provinces. Otherwise, each province has one or more pockets of significantly high breast cancer incidence. These are often located in more southerly areas, but they do not seem to be restricted to either urban or rural areas alone. Breast cancer rates are a health status indicator. They can be used to help assess health conditions. Health status refers to the state of health of a person or group, and measures causes of sickness and death. It can also include people’s assessment of their own health.

ContextFinancial and demographic pressures in US require an understanding of the most efficient distribution of physicians to maximize population-level health benefits. Prior work has assumed a constant negative relationship between physician supply and mortality outcomes throughout the US and has not addressed regional variation.MethodsIn this ecological analysis, geographically weighted regression was used to identify spatially varying relationships between local urologist density and prostate cancer mortality at the county level. Data from 1,492 counties in 30 eastern and southern states from 2006–2010 were analyzed.FindingsThe ordinary least squares (OLS) regression found that, on average, increasing urologist density by 1 urologist per 100,000 people resulted in an expected decrease in prostate cancer mortality of -0.499 deaths per 100,000 men (95% CI -0.709 to -0.289, p-value < 0.001), or a 1.5% decrease. Geographic weighted regression demonstrated that the addition of one urologist per 100,000 people in counties in the southern Mississippi River states of Arkansas, Mississippi, and Louisiana, as well as parts of Illinois, Indiana, and Wisconsin is associated with decrease of 0.411 to 0.916 in prostate cancer mortality per 100,000 men (1.6–3.6%). In contrast, the urologist density was not significantly associated with the prostate state mortality in the new England region.ConclusionsThe strength of association between urologist density and prostate cancer mortality varied regionally. Those areas with the highest potential for effects could be targeted for increasing the supply of urologists, as it associated with the largest predicted improvement in prostate cancer mortality.

BackgroundColorectal cancer (CRC) incidence rates have increased in younger individuals worldwide. We examined the most recent early- and late-onset CRC rates for the US.MethodsAge-standardized incidence rates (ASIR, per 100,000) of CRC were calculated using the US Cancer Statistics Database’s high-quality population-based cancer registry data from the entire US population. Results were cross-classified by age (20-49 [early-onset] and 50-74 years [late-onset]), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, American Indian/Alaskan Native, Asian/Pacific Islander), sex, anatomic location (proximal, distal, rectal), and histology (adenocarcinoma, neuroendocrine).ResultsDuring 2001 through 2018, early-onset CRC rates significantly increased among American Indians/Alaskan Natives, Hispanics, and Whites. Compared to Whites, early-onset CRC rates are now 21% higher in American Indians/Alaskan Natives and 6% higher in Blacks. Rates of early-onset colorectal neuroendocrine tumors have increased in Whites, Blacks, and Hispanics; early-onset colorectal neuroendocrine tumor rates are 2-times higher in Blacks compared to Whites. Late-onset colorectal adenocarcinoma rates are decreasing, while late-onset colorectal neuroendocrine tumor rates are increasing, in all racial/ethnic groups. Late-onset CRC rates remain 29% higher in Blacks and 15% higher in American Indians/Alaskan Natives compared to Whites. Overall, CRC incidence was higher in men than women, but incidence of early-onset distal colon cancer was higher in women.ConclusionsThe early-onset CRC disparity between Blacks and Whites has decreased, due to increasing rates in Whites—rates in Blacks have remained stable. However, rates of colorectal neuroendocrine tumors are increasing in Blacks. Blacks and American Indians/Alaskan Natives have the highest rates of both early- and late-onset CRC.ImpactOngoing prevention efforts must ensure access to and uptake of CRC screening for Blacks and American Indians/Alaskan Natives.

IntroductionSociodemographic disparities in genitourinary cancer-related mortality have been insufficiently studied, particularly across multiple cancer types. This study aimed to investigate gender, racial, and geographic disparities in mortality rates for the most common genitourinary cancers in the United States.MethodsMortality data for prostate, bladder, kidney, and testicular cancers were obtained from the Centers for Disease Control and Prevention (CDC) WONDER database between 1999 and 2020. Age-adjusted mortality rates (AAMRs) were analyzed by year, gender, race, urban–rural status, and geographic region using a significance level of p < 0.05.ResultsOverall, AAMRs for prostate, bladder, and kidney cancer declined significantly, while testicular cancer-related mortality remained stable. Bladder and kidney cancer AAMRs were 3–4 times higher in males than females. Prostate cancer mortality was highest in black individuals/African Americans and began increasing after 2015. Bladder cancer mortality decreased significantly in White individuals, Black individuals, African Americans, and Asians/Pacific Islanders but remained stable in American Indian/Alaska Natives. Kidney cancer-related mortality was highest in White individuals but declined significantly in other races. Testicular cancer mortality increased significantly in White individuals but remained stable in Black individuals and African Americans. Genitourinary cancer mortality decreased in metropolitan areas but either increased (bladder and testicular cancer) or remained stable (kidney cancer) in non-metropolitan areas. Prostate and kidney cancer mortality was highest in the Midwest, bladder cancer in the South, and testicular cancer in the West.DiscussionSignificant sociodemographic disparities exist in the mortality trends of genitourinary cancers in the United States. These findings highlight the need for targeted interventions and further research to address these disparities and improve outcomes for all populations affected by genitourinary cancers.

In 2022, Kentucky had the highest incidence of alcohol-associated cancer in the United States, with a rate of 145 per 100,000 people. This graph shows the rate of alcohol-related cancers per 100,000 people in the United States in 2022, by state.

The graph presents prostate cancer relative survival rates in the U.S. from 2001 to 2016, showing 1-year, 5-year, and 10-year relative survival percentages based on age groups. The x-axis represents age groups, while the y-axis indicates survival rates at different time intervals. Survival rates remain high across all age groups, with patients aged 65–69 having the highest 10-year survival rate of 99.5%. In contrast, men aged 80 and older have the lowest survival rates, with 92.1% at 1 year and 82.7% at 10 years. The data highlights that younger patients generally experience better long-term survival outcomes.

In 2022, there were 157 cases of prostate cancer per 100,000 population in the state of Louisiana, making it the state with the highest prostate cancer incidence rate that year. This statistic shows the incidence rate of prostate cancer in the U.S. in 2022, by state.

ObjectiveTriple negative breast cancer (TNBC) is a more aggressive subtype resistant to conventional treatments with a poorer prognosis. This study was to update the status of TNBC and the temporal changes of its incidence rate in the US.MethodsWomen diagnosed with breast cancer during 2011–2019 were obtained from the National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology and End Results (SEER) Program SEER*Stat Database which covers the entire population of the US. The TNBC incidence and its temporal trends by race, age, region (state) and disease stage were determined during the period.ResultsA total of 238,848 (or 8.8%) TNBC women were diagnosed during the study period. TNBC occurred disproportionally higher in women of Non-Hispanic Black, younger ages, with cancer at a distant stage or poorly/undifferentiated. The age adjusted incidence rate (AAIR) for TNBC in all races decreased from 14.8 per 100,000 in 2011 to 14.0 in 2019 (annual percentage change (APC) = −0.6, P = 0.024). Incidence rates of TNBC significantly decreased with APCs of −0.8 in Non-Hispanic White women, −1.3 in West and −0.7 in Northeastern regions. Women with TNBC at the age of 35–49, 50–59, and 60–69 years, and the disease at the regional stage displayed significantly decreased trends. Among state levels, Mississippi (20.6) and Louisiana (18.9) had the highest, while Utah (9.1) and Montana (9.6) had the lowest AAIRs in 2019. New Hampshire and Indiana had significant and highest decreases, while Louisiana and Arkansas had significant and largest increases in AAIR. In individual races, TNBC displayed disparities in temporal trends among age groups, regions and disease stages. Surprisingly, Non-Hispanic White and Hispanic TNBC women (0–34 years), and Non-Hispanic Black women (≥70 years) during the entire period, as well as Asian or Pacific Islander women in the South region had increased trends between 2011 and 2017.ConclusionOur study demonstrates an overall decreased trend of TNBC incidence in the past decade. Its incidence displayed disparities among races, age groups, regions and disease stages. Special attention is needed for a heavy burden in Non-Hispanic Black and increased trends in certain groups.